An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study.

摘要: Abstract Depression occurs frequently in post-stroke patients and appears to be associated with an impairment their rehabilitation functional recovery. Although selective serotonin reuptake inhibitors (SSRI) are often used depression (PSD), it has been observed that only a subset of is responsive this treatment. Other respond tricyclic antidepressants or MAO inhibitors, which, however, may not have favorable profile safety tolerability patients. In double-blinded, placebo-controlled study, we evaluated the efficacy noradrenaline inhibitor, reboxetine, PSD classified as affected by “retarded” depression. Reboxetine (4 mg, twice daily, for 16 weeks) was administered developed after single ischaemic hemorrhagic stroke. We assessed severity depressive symptoms Beck Inventory (BDI) Hamilton Rating Scale (HDRS). HDRS BDI scores (mean ± S.D.) at baseline were, respectively, 24 ± 1.31 19.87 ± 1.46 placebo group, 24.06 ± 1.52 20.56 ± 2.16 reboxetine group. After weeks, mean were respectively 22.73 ± 2.4 18.4 ± 3.33 9.26 ± 2.15 8.06 ± 3.43 group [p